|Systematic (IUPAC) name|
|Molecular mass||235.33 g/mol|
PF-592,379 is a drug developed by Pfizer which acts as a potent, selective and orally active agonist for the dopamine D3 receptor, which is under development as a potential medication for the treatment of female sexual dysfunction and male erectile dysfunction. Unlike some other less selective D3 agonists, PF-592,379 showed no evidence of abuse potential in animal studies, and so was selected for further development and potentially human clinical trials.
- Attkins, N.; Betts, A.; Hepworth, D.; Heatherington, A. C. (2010). "Pharmacokinetics and elucidation of the rates and routes of N-glucuronidation of PF-592379, an oral dopamine 3 agonist in rat, dog, and human". Xenobiotica 40 (11): 730–742. doi:10.3109/00498254.2010.514961. PMID 20836725.
- Collins, G. T.; Butler, P.; Wayman, C.; Ratcliffe, S.; Gupta, P.; Oberhofer, G.; Caine, S. B. (2012). "Lack of abuse potential in a highly selective dopamine D3 agonist, PF-592,379, in drug self-administration and drug discrimination in rats". Behavioural Pharmacology 23 (3): 280–291. doi:10.1097/FBP.0b013e3283536d21. PMC 3365486. PMID 22470105.